ImPact Biotech is pioneering a novel oncology technology platform known as Padeliporfin Vascular Targeted Photodynamic Therapy (VTP). This innovative approach aims to treat a variety of solid tumors, both at localized and metastatic stages, offering a promising alternative to traditional surgical methods. The VTP technology is designed to deliver surgery-like efficacy, particularly in cases where surgery may be too debilitating or where patients are ineligible for such procedures. By focusing on precision and safety, ImPact Biotech seeks to enhance the quality of life for cancer patients while addressing significant unmet medical needs in oncology.

One of the key areas of focus for ImPact Biotech is Upper Tract Urothelial Carcinoma (UTUC), a rare cancer affecting the ureters and renal pelvises. The company recognizes the challenges in managing this disease, particularly the difficulty of kidney-sparing procedures and the limited treatment options available. Padeliporfin VTP therapy is positioned as a potential solution for minimally invasive, targeted therapy, which could significantly improve patient outcomes. The ongoing ENLIGHTED pivotal clinical study, which has received FDA fast track designation, is a testament to the company's commitment to advancing this innovative treatment in the fight against UTUC.

Israel

ImPact Biotech is focused on the development and launch of Padeliporfin VTP (Vascular Targeted Photodynamic) therapy for the treatment of solid tumors. The company is headquartered in Israel, with presence in Luxembourg, France and USA, as well as its own GMP-certified (Good Manufacturing Practice) facility and research center in Israel.
ImPact Biotech holds exclusive rights from the Weizmann Institute of Science (WIS, Israel) and Memorial Sloan Kettering Cancer Center (MSKCC, New York), to develop and commercialize drugs and related technologies used in VTP.

ImPact Biotech

Company Details